Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QL1706 + lenvatinib + nab-paclitaxel + gemcitabine
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This combination therapy regimen is an investigational treatment being evaluated for first-line use in patients with advanced metastatic pancreatic cancer. The regimen integrates four distinct therapeutic agents: **QL1706**, **lenvatinib**, **nab-paclitaxel**, and **gemcitabine**. QL1706 is a novel bifunctional MabPair product developed by Qilu Pharmaceutical that simultaneously targets **PD-1** (iparomlimab) and **CTLA-4** (tuvonralimab), providing dual immune checkpoint inhibition to enhance anti-tumor T-cell activity. Lenvatinib is an oral multi-tyrosine kinase inhibitor that targets **VEGF** and **FGF** receptors, among others, to inhibit tumor angiogenesis and lymphangiogenesis. The chemotherapy component, known as the **AG regimen**, consists of nab-paclitaxel (albumin-bound paclitaxel) and gemcitabine, which are standard-of-care cytotoxic agents for pancreatic cancer. This multi-modal approach aims to combine the direct cytotoxic effects of chemotherapy with the anti-angiogenic and immunomodulatory effects of targeted and immunotherapy agents. The regimen is currently being studied in a Phase II clinical trial led by investigator Du Juan.
- Other names
- iparomlimab + tuvonralimab + lenvatinib + nab-paclitaxel + gemcitabineQL1706 + Lenvatinib + AG RegimenQL1706 + Lenvatinib + nab-paclitaxel + gemcitabine
02
Targets
PDGFRA (Platelet-derived growth factor receptor alpha)RNR (Ribonucleotide reductase)FGFR (FGFR family)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on QL1706 + lenvatinib + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QL1706 + lenvatinib + nab-paclitaxel + gemcitabine.